EMERGING THERAPIES IN THE TREATMENT OF COPD: EFFICACY AND FUTURE PROSPECTS

• DOI: https://doi.org/10.22533/at.ed.1595172511044

• Palavras-chave: COPD, GOLD 2025, Biomarkers, Personalized Management.

• Keywords: COPD, GOLD 2025, Biomarkers, Personalized Management.

• Abstract:

  Objective: To analyze the updates of the GOLD 2025 guidelines in the management of Chronic Obstructive Pulmonary Disease (COPD), highlighting the proposed changes and the new emerging therapies recommended, in addition to evaluating the theoretical and practical implications of these innovations in the treatment of the disease. Methodology: A literature review based on articles indexed in the PubMed database. The descriptors used in the search included "Chronic Obstructive Pulmonary Disease" AND "Ensifentrine" OR "Dupilumab" OR "Newtreatment" OR "Global Initiative for Chronic Obstructive Lung Disease". Twenty-two articles were selected for detailed analysis, considering their relevance to the topic. Discussion: The GOLD 2025 guidelines incorporated new diagnostic methods, such as impulse oscillometry and inflammatory biomarkers, as well as innovative therapies, such as Ensifentrine and Dupilumab, promoting a more personalized and effective approach. It was also noted that, despite advances, challenges such as limited access to technologies and the need for additional studies remain. Final considerations: The updates to the GOLD 2025 guidelines reflect significant advances in the approach to COPD, promoting a more individualized management based on recent evidence. The new recommendations aim to improve risk stratification, therapeutic efficacy and patients' quality of life, highlighting the importance of continuous monitoring of the evolution of the guidelines and the development of new therapeutic strategies.